Mallinckrodt Plc (NYSE:MNK)

16.16
Delayed Data
As of Feb 23
 +0.24 / +1.51%
Today’s Change
15.27
Today|||52-Week Range
54.90
-28.37%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.5B

Company Description

Mallinckrodt Plc operates as a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the following segments: Specialty Brands, Specialty Generics, and Nuclear Imaging. The Specialty Brands segment produces and markets branded pharmaceuticals and biopharmaceuticals. The Specialty Generics segment engages in the production of specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Nuclear Imaging segment manufactures and markets radiopharmaceuticals. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Staines-Upon-Thames, the United Kingdom.

Contact Information

Mallinckrodt Plc
3 Lotus Park
Staines-Upon-Thames Surrey TW18 3AG
P:441784636700
Investor Relations:

Employees

Shareholders

Individual stakeholders9.89%
Other institutional53.66%
Mutual fund holders47.49%

Top Executives

Mark C. TrudeauPresident, Chief Executive Officer & Director
Frank ScholzSenior Vice President-Global Operations
Matthew K. HarbaughChief Financial Officer & Senior Vice President
Steven RomanoChief Scientific Officer & Senior Vice President
Karen SheehyChief Compliance Officer